Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Accured Expenses (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Change in Accured Expenses for 14 consecutive years, with -$5.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 77.87% year-over-year to -$5.2 million, compared with a TTM value of -$2.2 million through Dec 2025, down 21.32%, and an annual FY2025 reading of $58000.0, up 101.03% over the prior year.
  • Change in Accured Expenses was -$5.2 million for Q4 2025 at Enanta Pharmaceuticals, down from $2.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $4.7 million in Q3 2021 and bottomed at -$6.7 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is -$197550.0, with a median of $669500.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses skyrocketed 939.85% in 2021, then crashed 277.88% in 2024.
  • Year by year, Change in Accured Expenses stood at $4.2 million in 2021, then crashed by 256.89% to -$6.6 million in 2022, then fell by 2.08% to -$6.7 million in 2023, then surged by 56.8% to -$2.9 million in 2024, then crashed by 77.87% to -$5.2 million in 2025.
  • Business Quant data shows Change in Accured Expenses for ENTA at -$5.2 million in Q4 2025, $2.4 million in Q3 2025, and $2.5 million in Q2 2025.